MX2022005270A - Derivados de quinolina y quinoxalina fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias. - Google Patents

Derivados de quinolina y quinoxalina fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias.

Info

Publication number
MX2022005270A
MX2022005270A MX2022005270A MX2022005270A MX2022005270A MX 2022005270 A MX2022005270 A MX 2022005270A MX 2022005270 A MX2022005270 A MX 2022005270A MX 2022005270 A MX2022005270 A MX 2022005270A MX 2022005270 A MX2022005270 A MX 2022005270A
Authority
MX
Mexico
Prior art keywords
dhodh
inhibitors
cancer
treatment
autoimmune
Prior art date
Application number
MX2022005270A
Other languages
English (en)
Inventor
Scott Kuduk
Justin Cisar
Colleen Keohane
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2022005270A publication Critical patent/MX2022005270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

La presente invención describe compuestos de la Fórmula (I): (?) en donde X es CH; Los presentes compuestos de la Fórmula (I) son inhibidores de dihidroorotato deshidrogenasa (DHODH) y son útiles para el tratamiento de trastornos inflamatorios, trastornos autoinmunes y cáncer, tales como, p. ej., linfomas, leucemias, carcinomas y sarcomas. La presente descripción describe la síntesis y caracterización de compuestos ilustrativos así como datos farmacológicos de estos (p. ej., páginas 60 a 136; ejemplos 1 al 39; tablas 1 y 2). Un compuesto ilustrativo es, p. ej.: 4-etil-1-(7-fluoro-4-isopropil-2- (2-metoxifenil)quinolin-6-il)-3- (hidroximetil)-1H-1,2,4-triazol-5(4H)-ona (ejemplo 1): (AA).
MX2022005270A 2019-11-01 2020-10-30 Derivados de quinolina y quinoxalina fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias. MX2022005270A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962929163P 2019-11-01 2019-11-01
PCT/IB2020/060221 WO2021084500A1 (en) 2019-11-01 2020-10-30 Fluorinated quinoline and quinoxaline derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors for the treatment of cancer, autoimmune and inflammatory diseases

Publications (1)

Publication Number Publication Date
MX2022005270A true MX2022005270A (es) 2022-06-09

Family

ID=73198375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005270A MX2022005270A (es) 2019-11-01 2020-10-30 Derivados de quinolina y quinoxalina fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias.

Country Status (10)

Country Link
US (1) US20230037448A1 (es)
EP (1) EP4051672A1 (es)
JP (1) JP2023500252A (es)
KR (1) KR20220097438A (es)
CN (1) CN114650988A (es)
AU (1) AU2020377205A1 (es)
BR (1) BR112022007981A2 (es)
CA (1) CA3159578A1 (es)
MX (1) MX2022005270A (es)
WO (1) WO2021084500A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3184985A1 (en) * 2020-07-14 2022-01-20 Nanjing Zenshine Pharmaceuticals Co., Ltd. Compounds as dhodh inhibitors
WO2022200615A1 (en) 2021-03-26 2022-09-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Pyrimidine biosynthesis inhibitor combination for use in treating viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009544631A (ja) * 2006-07-25 2009-12-17 エンビボ ファーマシューティカルズ インコーポレイテッド キノリン誘導体
EP2113503A1 (en) * 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
JP2014522837A (ja) * 2011-06-29 2014-09-08 大塚製薬株式会社 治療用化合物としてのキナゾリン及び関連の使用方法
KR102029124B1 (ko) * 2015-08-27 2019-10-07 화이자 인코포레이티드 Irak4 조정제로서의 비시클릭-융합된 헤테로아릴 또는 아릴 화합물
EP3553052A1 (en) * 2018-04-10 2019-10-16 Bayer AG 5-oxo-4,5-dihydro-1h-1,2,4-triazol derivatives for the treatment of cancer

Also Published As

Publication number Publication date
WO2021084500A1 (en) 2021-05-06
CA3159578A1 (en) 2021-05-06
AU2020377205A1 (en) 2022-06-16
US20230037448A1 (en) 2023-02-09
EP4051672A1 (en) 2022-09-07
CN114650988A (zh) 2022-06-21
BR112022007981A2 (pt) 2022-07-05
JP2023500252A (ja) 2023-01-05
KR20220097438A (ko) 2022-07-07

Similar Documents

Publication Publication Date Title
JP7317028B2 (ja) 抗ガン剤として有用な置換キナゾリン誘導体と置換ピリドピリミジン誘導体
MX2022005270A (es) Derivados de quinolina y quinoxalina fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias.
MY148986A (en) Heterocyclic janus kinase 3 inhibitors
US4912106A (en) 5,6-Dihydro-2-(substituted phenyl)-1,2,4-triazine-3,5,(2H,4H)-diones and their use as protozoa combating agents
MA27801A1 (fr) Nouveaux composes heterocycliques pour le traitement des affections inflammatoires et allergiques, leur procede de preparation et compositions pharmaceutiques les contenant
ATE503483T1 (de) Hemmer der akt aktivität
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
US7019002B2 (en) Pyridopyrimidinones derivatives as telomerase inhibitors
ATE446752T1 (de) Hemmer der akt aktivität
CR8148A (es) Derivados del indazolil (indolil) maleimida sustituidos como inhibidores de la cinasa
ATE461179T1 (de) Hemmer der akt aktivität
CR20210626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
FI90235B (fi) Menetelmä eläinlääketieteellisesti käyttökelpoisten -aryyli-4-(4,5-dihydro-3,5-diokso-1,2,4-triatsin-2(3H)-yyli)bentseeniasetonitriilien valmistamiseksi
MX2022005258A (es) Derivados de benzo[b][1,4]oxazina, quinoxalina y quinolona fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias.
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
MA54133A (fr) Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y
NO20063747L (no) Substituerte kinoliner og deres anvendelse som mykobakterielle inhibitorer
CL2023001461A1 (es) Inhibidores de prmt5 novedosos
US9120780B2 (en) Indole or indazole derivative or salt thereof
KR101894096B1 (ko) Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이의 용도
JPWO2019235553A5 (es)
HUP0401115A2 (hu) Szívbetegségek és allergiák kezelésére alkalmas, PDE IV-gátló és TNF-antagonista hatású 4-(benzilidén-amino)-3-(metil-szulfanil)-4H-[1,2,4]triazin-5-on-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
EA202191349A1 (ru) 1,3,4-оксадиазолон и фармацевтический препарат
MEP25308A (en) Aminoindazole derivatives and use thereof as kinase inhibitors